-
Je něco špatně v tomto záznamu ?
Residual OXPHOS is required to drive primary and metastatic lung tumours in an orthotopic breast cancer model
P. Herst, G. Carson, D. Lewthwaite, D. Eccles, A. Schmidt, A. Wilson, C. Grasso, D. O'Sullivan, J. Neuzil, M. McConnell, M. Berridge
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Fast adaptation of glycolytic and mitochondrial energy pathways to changes in the tumour microenvironment is a hallmark of cancer. Purely glycolytic ρ0 tumour cells do not form primary tumours unless they acquire healthy mitochondria from their micro-environment. Here we explored the effects of severely compromised respiration on the metastatic capability of 4T1 mouse breast cancer cells. METHODS: 4T1 cell lines with different levels of respiratory capacity were generated; the Seahorse extracellular flux analyser was used to evaluate oxygen consumption rates, fluorescent confocal microscopy to assess the number of SYBR gold-stained mitochondrial DNA nucleoids, and the presence of the ATP5B protein in the cytoplasm and fluorescent in situ nuclear hybridization was used to establish ploidy. MinION nanopore RNA sequence analysis was used to compare mitochondrial DNA transcription between cell lines. Orthotopic injection was used to determine the ability of cells to metastasize to the lungs of female Balb/c mice. RESULTS: OXPHOS-deficient ATP5B-KO3.1 cells did not generate primary tumours. Severely OXPHOS compromised ρ0D5 cells generated both primary tumours and lung metastases. Cells generated from lung metastasis of both OXPHOS-competent and OXPHOS-compromised cells formed primary tumours but no metastases when re-injected into mice. OXPHOS-compromised cells significantly increased their mtDNA content, but this did not result in increased OXPHOS capacity, which was not due to decreased mtDNA transcription. Gene set enrichment analysis suggests that certain cells derived from lung metastases downregulate their epithelial-to-mesenchymal related pathways. CONCLUSION: In summary, OXPHOS is required for tumorigenesis in this orthotopic mouse breast cancer model but even very low levels of OXPHOS are sufficient to generate both primary tumours and lung metastases.
Department of Cancer Cell Biology Malaghan Institute of Medical Research Wellington New Zealand
Department of Radiation Therapy University of Otago Wellington New Zealand
Institute of Biotechnology of the Czech Academy of Sciences Prague West Czechia
School of Biological Sciences Victoria University of Wellington Wellington New Zealand
School of Pharmacy and Medical Science Griffith University Southport QLD Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24012868
- 003
- CZ-PrNML
- 005
- 20240726151432.0
- 007
- ta
- 008
- 240723e20240501sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fonc.2024.1362786 $2 doi
- 035 __
- $a (PubMed)38751813
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Herst, Patries $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand $u Department of Radiation Therapy, University of Otago, Wellington, New Zealand
- 245 10
- $a Residual OXPHOS is required to drive primary and metastatic lung tumours in an orthotopic breast cancer model / $c P. Herst, G. Carson, D. Lewthwaite, D. Eccles, A. Schmidt, A. Wilson, C. Grasso, D. O'Sullivan, J. Neuzil, M. McConnell, M. Berridge
- 520 9_
- $a BACKGROUND: Fast adaptation of glycolytic and mitochondrial energy pathways to changes in the tumour microenvironment is a hallmark of cancer. Purely glycolytic ρ0 tumour cells do not form primary tumours unless they acquire healthy mitochondria from their micro-environment. Here we explored the effects of severely compromised respiration on the metastatic capability of 4T1 mouse breast cancer cells. METHODS: 4T1 cell lines with different levels of respiratory capacity were generated; the Seahorse extracellular flux analyser was used to evaluate oxygen consumption rates, fluorescent confocal microscopy to assess the number of SYBR gold-stained mitochondrial DNA nucleoids, and the presence of the ATP5B protein in the cytoplasm and fluorescent in situ nuclear hybridization was used to establish ploidy. MinION nanopore RNA sequence analysis was used to compare mitochondrial DNA transcription between cell lines. Orthotopic injection was used to determine the ability of cells to metastasize to the lungs of female Balb/c mice. RESULTS: OXPHOS-deficient ATP5B-KO3.1 cells did not generate primary tumours. Severely OXPHOS compromised ρ0D5 cells generated both primary tumours and lung metastases. Cells generated from lung metastasis of both OXPHOS-competent and OXPHOS-compromised cells formed primary tumours but no metastases when re-injected into mice. OXPHOS-compromised cells significantly increased their mtDNA content, but this did not result in increased OXPHOS capacity, which was not due to decreased mtDNA transcription. Gene set enrichment analysis suggests that certain cells derived from lung metastases downregulate their epithelial-to-mesenchymal related pathways. CONCLUSION: In summary, OXPHOS is required for tumorigenesis in this orthotopic mouse breast cancer model but even very low levels of OXPHOS are sufficient to generate both primary tumours and lung metastases.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Carson, Georgia $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
- 700 1_
- $a Lewthwaite, Danielle $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand $u School of Biological Sciences , Victoria University of Wellington, Wellington, New Zealand
- 700 1_
- $a Eccles, David $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
- 700 1_
- $a Schmidt, Alfonso $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
- 700 1_
- $a Wilson, Andrew $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
- 700 1_
- $a Grasso, Carole $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
- 700 1_
- $a O'Sullivan, David $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
- 700 1_
- $a Neuzil, Jiri $u Institute of Biotechnology of the Czech Academy of Sciences, Prague-West, Czechia $u School of Pharmacy and Medical Science, Griffith University, Southport, QLD, Australia
- 700 1_
- $a McConnell, Melanie $u School of Biological Sciences , Victoria University of Wellington, Wellington, New Zealand
- 700 1_
- $a Berridge, Michael $u Department of Cancer Cell Biology, Malaghan Institute of Medical Research, Wellington, New Zealand
- 773 0_
- $w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 14 (20240501), s. 1362786
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38751813 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151425 $b ABA008
- 999 __
- $a ok $b bmc $g 2125502 $s 1224731
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 14 $c - $d 1362786 $e 20240501 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
- LZP __
- $a Pubmed-20240723